
    
      Randomized, open-label assignment of type 2 patients who are on a stable antidiabetic regimen
      to treatment with either insulin glargine or BID NPH human insulin, with baseline diabetic
      retinopathy of severity 53/<53 on the ETDRS scale, for 5 years of followup. Outcomes measured
      by seven-field fundus photography at baseline, 1.5, 3,6,and 9 months, and annually.
    
  